ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0422

Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica

Sebastian Sattui1, Deanna Jannat-Khah2, Lindsay Lally1, Sarah Lieber1, Lisa Mandl1 and Robert Spiera3, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York City, NY, 3Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY

Meeting: ACR Convergence 2020

Keywords: Aging, Polymyalgia Rheumatica (PMR), quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors. Frailty and pre-frailty have been reported in 10% and 44%of community dwelling elderly, respectively.1 Chronic inflammation is a risk factor for frailty. Patients with PMR represent a population at high risk for frailty; however, there are no data on the prevalence and impact of frailty in PMR patients. The objective of this study is to describe the prevalence of frailty in a single center cohort of patients with PMR and to determine the association of frailty with health-related quality of life (HRQoL), cognition and sarcopenia.

Methods: Patients with an ICD-10 diagnosis of PMR were identified between 03/2019-03/2020. Patients fulfilling 2012 EULAR/ACR Provisional Classification Criteria, ≤ 12 months from diagnosis and on glucocorticoids (≥ 3 mg of prednisone) were included. Disease activity was measured with the PMR-activity score. Frailty and pre-frailty were defined according to Fried Frailty Criteria2. HRQoL was assessed using global Patient-Reported Outcomes Measurement Information System (PROMIS) computerized adaptive tests where 50 is the population mean. Cognition was assessed using the Mini-Mental Standard Examination (MMSE) and sarcopenia was assessed by DXA3. Fisher’s exact test, chi-square tests and Kruskal-Wallis tests were used to describe differences among groups as appropriate. Univariate and multivariate linear regressions were used to describe the associations with frailty.

Results: 40 patients were enrolled. Overall, patients had a low burden of comorbidities and high education level (Table 1). Prevalence of frailty, pre-frailty and robustness was 15%,60% and 25%, respectively. Frail patients were older and had longer duration of disease; however, these differences were not statistically significant. Of 27 patients with body composition analysis, 26% were sarcopenic. Frail patients had worse physical function (lower scores) and more fatigue, pain behavior and interference (higher scores) compared to pre-frail and robust patients (Table 2). In the multivariate analysis, frail patients were more likely to have worse physical function, more fatigue, and more pain behavior and pain interference. No significant associations between either cognition or sarcopenia and frailty were observed.

Conclusion: In this cohort of PMR patients, we found a higher prevalence of frailty and pre-frailty than community dwelling elderly. Frailty was associated with worse physical function and increased fatigue, pain behavior and pain interference, differences that were clinically meaningful and statistically significant. Study limitations include the relatively small, homogenous sample size and missing data regarding sarcopenia. These data suggest that frailty is common in PMR and that it is associated with clinical phenotypes. Further assessment of frailty and its impact on PMR outcomes in a larger prospective cohort is warranted.

References

  1. Collard RM et al. 2012
  2. Bandeen-Roche et al. 2006
  3. Cruz-Jentoftet al. 2019

Figure 1. Fried Frailty Classification

Table 1. Baseline characteristics by frailty classification

Table 2. HRQoL, MMSE and Sarcopenia by frailty classification and Multivariate Cross-Sectional Analysis


Disclosure: S. Sattui, None; D. Jannat-Khah, Astrazeneca, 1, Cytodyn, 1, Walgreens Boots Alliance, 1; L. Lally, None; S. Lieber, None; L. Mandl, Annals of Internal Medicine, 9, UpToDate, 7, Regeneron, 2; R. Spiera, Roche-Genentech, 1, 2, GlaxoSmithKline, 1, 2, Bristol-Myers Squibb, 1, Boehringer Ingelheim, 1, ChemoCentryx, 1, Corbus Pharmaceuticals, 1, Sanofi, 1, InflaRx, 1, Janssen, 1, Forbius, 1, 2.

To cite this abstract in AMA style:

Sattui S, Jannat-Khah D, Lally L, Lieber S, Mandl L, Spiera R. Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/frailty-and-health-related-quality-of-life-in-patients-with-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frailty-and-health-related-quality-of-life-in-patients-with-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology